| 刘德孔.奥曲肽联合前列地尔治疗肝硬化合并肝肾综合征疗效及对患者降钙素原和肝肾功能影响[J].浙江中西医结合杂志,2017,27(6): |
| 奥曲肽联合前列地尔治疗肝硬化合并肝肾综合征疗效及对患者降钙素原和肝肾功能影响 |
| Octreotide combined with alprostadil in the treatment of liver cirrhosis with hepatorenal syndrome and curative effect of procalcitonin in patients with liver and kidney function |
| 投稿时间：2016-10-26 修订日期：2016-12-10 |
| DOI： |
| 中文关键词: 奥曲肽 前列地尔 肝硬化合并肝肾综合征 疗效 降钙素原 肝肾功能 |
| 英文关键词:octreotide alprostadil liver cirrhosis with hepatorenal syndrome curative effect procalcitonin liver function |
| 基金项目: |
|
| 摘要点击次数: 805 |
| 全文下载次数: 1 |
| 中文摘要: |
| 目的：探讨奥曲肽联合前列地尔治疗肝硬化合并肝肾综合征疗效及对患者降钙素原和肝肾功能的影响。方法：肝硬化合并肝肾综合征患者92例依据随机数字表法随机分为观察组46例与对照组46例。观察组采用奥曲肽联合前列地尔治疗,对照组仅采用前列地尔治疗。两组疗程均为14 d。结果：观察组治疗总有效率(86.96%)高于对照组(69.57%)(P<0.05)；两组PCT含量治疗后下降(P<0.05)；观察组PCT含量治疗后低于对照组(P<0.05)；两组ALT和TBIL含量治疗后下降(P<0.05)；观察组ALT和TBIL含量治疗后低于对照组(P<0.05)；两组Scr、BUN含量治疗后下降,而24 h尿量治疗后增加(P<0.05)；观察组Scr、BUN含量治疗后低于对照组, 而24 h尿量治疗后高于对照组(P<0.05)；两组均未发生严重不良反应。结论：奥曲肽联合前列地尔治疗肝硬化合并肝肾综合征疗效显著,且可降低血清降钙素原水平,及改善患者肝肾功能,具有重要研究价值。 |
| 英文摘要: |
| Objective: To investigate the effect of octreotide combined with alprostadil in the treatment of liver cirrhosis with hepatorenal syndrome and effect of calcitonin on patients with primary and liver and kidney function. Methods: 92 cases of cirrhosis with liver and kidney syndrome were randomly divided into observation group 46 cases and control group 46 cases. The observation group were treated with octreotide combined with alprostadil treatment, the control group only treated by alprostadil. The course of treatment in the two groups was 14 d. Results: the total efficiency of the observation group (86.96%) was higher than the control group (69.57%) (P<0.05); the content of PCT decreased after treatment of the two groups (P<0.05); the observation group PCT was lower than the control group after treatment (P<0.05); treatment group two ALT and TBIL were decreased (P<0.05); ALT and TBIL in the observation group lower than the control group after treatment (P<0.05); two groups of Scr, BUN content decreased after treatment, and 24 h urine volume increased after treatment (P<0.05); the observation group Scr, BUN were lower than the control group after treatment, 24 h urinary volume after treatment is higher than that of control group (P<0.05); the two groups were not serious adverse reaction. Conclusion: octreotide combined with alprostadil in the treatment of liver cirrhosis with hepatorenal syndrome curative effect is distinct, and can reduce the serum procalcitonin level, and improve the function of liver and kidney, has the important research value. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
